{"filings":[{"id":442921,"accession_number":"0001193125-26-224065","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2026-05-14T20:15:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro Q1 cash $202.6M; revenue $14.5M; luvelta closed; STRO-004 data mid-2026","event_type":"earnings","confidence":"high","bullets":["Cash $202.6M as of Mar 31, 2026 (vs $141.4M Dec 2025); $110M stock offering extends runway into Q2 2028.","Q1 revenue $14.5M (down from $17.4M YoY); total R&D+G&A $44.1M (down from $64.9M YoY).","STRO-004 Phase 1 dose-escalation ongoing; initial safety, PK, activity data expected mid-2026.","Astellas collaboration: first TROP2 dual-payload iADC in clinic; $10M milestone received April 2026.","Luvelta program closed; no further investment or business development efforts."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":14523000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103429,"accession_number":"0001193125-26-119844","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["1.02","2.02","9.01"],"status":"ready","headline":"Sutro Biopharma reports FY2025 revenue $102.5M; cash runway extended into Q2 2028","event_type":"earnings","confidence":"medium","bullets":["Cash $141.4M at Dec 31, 2025; $110M underwritten offering extends runway into Q2 2028.","Revenue $102.5M (FY2025) vs $62.0M in 2024; R&D+G&A expenses reduced to $207.4M from $300.5M.","Terminated ATM Sales Agreement with Jefferies effective March 23, 2026.","STRO-004 Phase 1 dosed three cohorts; initial data mid-2026. STRO-227 IND submission on track for 2026.","Astellas TROP2 iADC program entered clinic; $10M milestone expected Q2 2026. Second program triggers $7.5M milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103428,"accession_number":"0001193125-26-044934","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Sutro Biopharma raises $110M in underwritten public offering of 7.87M shares at $13.98/share","event_type":"other_material","confidence":"high","bullets":["Offering of 7,868,383 shares at $13.98 per share; gross proceeds approximately $110.0 million.","Underwriters include Leerink Partners and TD Securities; closing expected February 11, 2026.","Proceeds to fund research, clinical development, manufacturing, and general corporate purposes.","Combined with existing cash, total capital resources estimated at $251.4 million; cash runway into Q2 2028.","Offering made under existing shelf registration statement; customary underwriting agreement terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119673,"accession_number":"0001193125-25-322859","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sutro Biopharma regains Nasdaq minimum bid price compliance after prior deficiency","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on Dec 17, 2025 confirming compliance with Listing Rule 5450(a)(1) after 10 consecutive business days with closing bid at or above $1.00.","Non-compliance was initially disclosed on June 20, 2025 when bid price fell below $1.00 for 30 consecutive business days.","Listing matter is now closed; company meets all other Nasdaq Global Market continued listing criteria."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119672,"accession_number":"0001193125-25-306786","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Sutro Biopharma announces 1-for-10 reverse stock split effective Dec 3 to regain Nasdaq compliance","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-10, effective 12:01 a.m. ET on December 3, 2025.","Outstanding shares reduced from ~85.2M to ~8.52M; symbol STRO unchanged, new CUSIP 869367201.","Intended to regain Nasdaq minimum bid price compliance; approved by stockholders on June 6, 2025.","No fractional shares issued; any fractional interest rounded up to nearest whole share.","Proportionate adjustments to equity awards, exercise prices, and shares reserved under equity plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119671,"accession_number":"0001193125-25-269833","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro Biopharma Q3 revenue $9.7M, cash $167.6M; IND cleared for STRO-004","event_type":"earnings","confidence":"high","bullets":["FDA cleared IND for STRO-004 (Tissue Factor ADC); first patient dosing expected before year-end.","Cash, cash equivalents and marketable securities were $167.6M at Sept. 30, 2025, down from $388.3M a year earlier.","Revenue was $9.7M (vs $8.5M Q3 2024), primarily from Astellas collaboration.","R&D and G&A expenses totaled $48.6M, down from $76.4M in Q3 2024.","Organizational restructuring expected to extend cash runway into at least mid-2027; restructuring costs estimated at $4.1M–$4.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":90837000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136245,"accession_number":"0001193125-25-223434","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Sutro Biopharma cuts workforce ~33%; extends cash runway to mid-2027","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of approximately one-third to prioritize three preclinical ADC programs.","Expected cash runway extended into at least mid-2027 due to restructuring and milestone payments.","Initial clinical data from STRO-004 (Tissue Factor-targeting exatecan ADC) expected in 2026.","Restructuring costs estimated at $4.1-4.3 million, with majority paid in Q4 2025.","Company plans to initiate clinical studies for at least one additional ADC program beyond STRO-004."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136244,"accession_number":"0000950170-25-105159","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro Q2 revenue $63.7M; cash $205.1M; STRO-004 IND on track for H2 2025","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $63.7M, up 148% YoY, driven by Astellas collaboration and Ipsen deferred revenue recognition.","Cash, equivalents and marketable securities $205.1M; cash runway into early 2027.","R&D and G&A expenses $48.7M (down 35% YoY); restructuring costs $18.4M from luvelta deprioritization.","STRO-004 FIH trial on track for H2 2025; STRO-006 clinical in 2026; dual-payload ADC IND filing in 2027.","Astellas milestone triggered $7.5M payment; Ipsen terminates STRO-003; Greg Chow appointed CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":81144000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153321,"accession_number":"0000950170-25-089978","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Sutro Biopharma receives Nasdaq minimum bid price deficiency notice; has until Dec 17, 2025 to cure","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Sutro on June 20, 2025 of non-compliance with $1.00 minimum bid price rule.","Company has 180 calendar days, until December 17, 2025, to regain compliance by closing at $1.00 for 10 consecutive days.","If not cured, Sutro may transfer to Nasdaq Capital Market for a second 180-day period or face delisting.","Sutro plans to monitor bid price and may implement a reverse stock split if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153320,"accession_number":"0001193125-25-138481","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sutro Biopharma stockholders approve reverse stock split at 1:5 to 1:25 ratio","event_type":"other_material","confidence":"high","bullets":["Reverse stock split authorized at ratio between 1:5 and 1:25, board to set exact ratio.","Three Class I directors elected: Heidi Hunter, Jon Wigginton, Michael Dybbs for three-year terms.","Ernst & Young LLP ratified as independent auditor for fiscal year ending Dec 2025 with 99.1% for.","Non-binding advisory vote on named executive officer compensation passed with 42.99M for.","All proposals passed at June 6, 2025 annual meeting; broker non-votes ranged from 12.5M on director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153319,"accession_number":"0001193125-25-133268","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sutro Biopharma appoints Gregory K. Chow as CFO effective June 2, 2025","event_type":"leadership","confidence":"high","bullets":["Gregory K. Chow appointed CFO, principal financial and accounting officer, effective June 2, 2025.","Base salary $475,000; target annual bonus 40% of base salary.","Receives option for 275,000 shares (4-year vest) and 100,000 RSUs (4-year vest).","Prior roles: CFO of NodThera (Aug 2024-Mar 2025), Freenome (Jan-Aug 2024), Frontier Medicines (Mar 2021-Dec 2024).","Severance on non-cause termination: 15 months salary + pro-rata bonus + COBRA; full acceleration upon change in control within 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}